The global postoperative nausea and vomiting (PONV) management market garnered a market value of US$ 1.04 Billion in 2022 and is expected to accumulate a market value of US$ 3.9 Billion by registering a CAGR of 12.8% in the forecast period 2023 to 2033. Growth of the postoperative nausea and vomiting (PONV) management market can be attributed to increasing number of surgeries being performed and the growing awareness of the importance of managing PONV for patient comfort and safety. The market for postoperative nausea and vomiting (PONV) management registered a CAGR of 7.4% in the historical period 2018 to 2022
Postoperative nausea and vomiting (PONV) management refers to the various strategies and interventions used to prevent or treat nausea and vomiting in patients after surgery. PONV is a common side effect of anesthesia and surgery, affecting up to 80% of patients in some cases. It can cause discomfort, dehydration, electrolyte imbalances, and delayed recovery.
PONV management typically involves a combination of pharmacological and non-pharmacological interventions, such as antiemetic medications, IV fluids, and the use of acupressure or acupuncture. Effective PONV management is essential for patient comfort and recovery after surgery, and can also help prevent complications such as aspiration pneumonia and wound dehiscence.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 1.17 Billion |
| Anticipated Forecast Value (2033) | US$ 3.9 Billion |
| Projected Growth Rate (2023 to 2033) | 12.8% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Postoperative nausea and vomiting (PONV) management reflected a value of 7.4% during the historical period, 2018 to 2022.
The PONV management market has been growing steadily in recent years due to several factors, including an increasing number of surgeries being performed worldwide, growing awareness of the importance of PONV management for patient comfort and safety, and the development of new and effective antiemetic medications.
Several factors are driving the growth of the PONV management market, including the increasing prevalence of PONV, the development of new and effective antiemetic medications, and the adoption of non-pharmacological approaches to PONV management.
Thus, the market for postoperative nausea and vomiting (PONV) management is expected to register a CAGR of 12.8% in the forecast period 2023 to 2033.
Increasing number of surgeries driving growth of PONV market
The growing number of surgeries being performed globally is a key driver of the PONV management market. As the number of surgeries increases, the incidence of PONV also rises, leading to a greater demand for effective PONV management solutions.
The development of new and more effective antiemetic medications is another important driver of the PONV management market. These medications can provide better control of PONV symptoms, resulting in improved patient outcomes and satisfaction.
Healthcare providers are increasingly aware of the importance of managing PONV for patient comfort and safety. This has led to greater adoption of PONV management protocols and the use of a range of pharmacological and non-pharmacological interventions.
The development of new technologies, such as electronic stimulation devices, has expanded the range of PONV management solutions available to healthcare providers. These technologies provide non-pharmacological options that can be used in conjunction with antiemetic medications to improve PONV management outcomes.
Principal Consultant
Pharmacological Interventions
Antiemetic Medications: Antiemetic medications are the most commonly used pharmacological intervention for PONV management. These medications work by blocking specific receptors in the brain that are responsible for inducing nausea and vomiting. Some of the commonly used antiemetic medications include ondansetron, dexamethasone, and metoclopramide.
Anesthetic Technique: The choice of anesthetic technique used during surgery can also impact the incidence of PONV. Regional anesthesia, such as spinal or epidural anesthesia, has been shown to be associated with a lower incidence of PONV compared to general anesthesia.
Non-Pharmacological Interventions
Acupuncture: Acupuncture involves the insertion of fine needles into specific points on the body to stimulate nerve pathways and promote healing. It has been shown to be effective in reducing the incidence of PONV.
Acupressure: Acupressure involves the application of pressure to specific points on the body to stimulate nerve pathways and promote healing. It has been shown to be effective in reducing the incidence of PONV.
Transcutaneous Electrical Nerve Stimulation (TENS): TENS involves the use of small electrical currents to stimulate nerve pathways and promote healing. It has been shown to be effective in reducing the incidence of PONV.
Side effects of antiemetics and expensive nature of PONV management hampering market growth
Patients vary widely in their susceptibility to PONV, and it can be difficult to predict who will experience it. This variability makes it challenging for healthcare providers to tailor treatments to individual patients.
Antiemetic medications are commonly used to manage PONV, but they can have side effects such as sedation, dizziness, and dry mouth. These side effects can be particularly problematic for patients who are already recovering from surgery.
Antiemetic medications can be expensive, and their cost can be a barrier to access for some patients. This can limit the ability of healthcare providers to provide effective PONV management. There is a lack of standardization in the management of PONV, with different healthcare providers using different protocols and medications. This can lead to inconsistency in care and can make it difficult to compare outcomes across different facilities.
Prevention is key to managing PONV, but it can be challenging to identify patients who are at high risk and to implement appropriate preventive measures. This can result in a higher incidence of PONV and increased costs associated with treatment. Some patients and healthcare providers may not be aware of the risks associated with PONV, or may not take it seriously enough. This can lead to inadequate management and can result in unnecessary suffering for patients.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Increasing number of surgeries performed in the region boosting market growth
The North America postoperative nausea and vomiting (PONV) management market is a significant segment of the global PONV management market. North America comprises of developed countries such as the United States and Canada, which have well-established healthcare systems and advanced medical technologies.
The market growth can be attributed to factors such as the increasing number of surgical procedures, rising geriatric population, and the growing prevalence of PONV. The United States dominates the North America PONV management market due to the presence of a large number of hospitals, advanced healthcare infrastructure, and high healthcare expenditure.
According to the Centers for Disease Control and Prevention (CDC), there were around 50 Billion surgeries performed in the United States in 2017, which is expected to increase in the coming years. This high number of surgeries creates a significant demand for PONV management products and services.
The major players in the North America PONV management market include Acacia Pharma Group plc, Heron Therapeutics, Inc., Merck & Co., Inc., Eisai Co., Ltd., and GlaxoSmithKline plc. These companies are focused on developing innovative products and technologies to improve PONV management, which is expected to drive market growth in the region. Thus, North America is expected to possess 47% market share for PONV management market in 2023.
Technological advancements creating lucrative opportunities for PONV management in Europe
PONV is a common complication of surgery and affects a significant proportion of patients. According to a study published in the European Journal of Anaesthesiology, the incidence of PONV in Europe ranges from 10% to 80% depending on the type of surgery and patient characteristics. The increasing prevalence of PONV is driving the demand for effective PONV management products and services.
The number of surgical procedures performed in Europe is increasing, driven by factors such as the aging population, changing lifestyles, and advancements in medical technology. This creates a significant demand for PONV management products and services.
There have been significant technological advancements in the field of PONV management, such as the development of new antiemetic drugs and the use of non-pharmacological interventions such as acupuncture and acupressure. These advancements are improving the effectiveness of PONV management and are driving market growth.
Governments in Europe are taking initiatives to improve the quality of healthcare and reduce the burden of postoperative complications such as PONV. For example, the European Society of Anaesthesiology has published guidelines for the management of PONV, which are expected to improve the quality of care and drive market growth.
There is growing awareness among patients and healthcare providers about the risks associated with PONV and the importance of effective management. This is driving demand for PONV management products and services. Thus, Europe is expected to possess 43% market share for PONV management market in 2023.
Timely administration favoring growth of hospital pharmacies for PONV management
Hospital pharmacies have direct access to a wide range of antiemetic medications that are commonly used for PONV management. This allows healthcare providers to quickly obtain the appropriate medications for patients who are experiencing PONV.
Hospital pharmacists are highly trained professionals who have a thorough understanding of medication management, including the appropriate use of antiemetics. They can provide guidance on medication selection, dosing, and potential drug interactions, which is essential for effective PONV management.
PONV can occur rapidly and may require immediate intervention. Hospital pharmacies are often located within the hospital or adjacent to the surgical suite, which allows for timely administration of antiemetic medications as needed. In addition to medications, hospital pharmacies may have access to specialized equipment such as intravenous pumps, which can be used for the administration of antiemetic medications.
Compliance with regulations: Hospital pharmacies are subject to strict regulatory requirements, which ensures that medications are stored, dispensed, and administered in a safe and appropriate manner. This is particularly important for PONV management, as many antiemetic medications have the potential for adverse effects. Thus, hospital pharmacies are expected to possess 49% market share for PONV management market in 2023.
Key players in the postoperative nausea and vomiting (PONV) management market are Acacia Pharma, Hoffmann-La Roche AG, Novartis AG, Ani Pharmaceuticals, Inc, Camurus AB, Sanofi S.A., Helsinn Holding S.A., Eisai Corporation, Merck and Co., GlaxoSmithKline Corporation
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 1.17 Billion |
| Market Value in 2033 | US$ 3.9 Billion |
| Growth Rate | CAGR of 12.8% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The market was valued at US$ 1.04 billion in 2022.
The market is estimated to secure a valuation of US$ 1.17 billion in 2023.
The market is forecast to register a CAGR of 12.8% through 2033.
An increasing number of surgeries drives growth in the PONV market.
Acacia Pharma, Hoffmann-La Roche AG, and Novartis AG are the key players in the market.
1. Executive Summary | Postoperative Nausea and Vomiting (PONV) Management Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033
5.3.1. Serotonin Antagonists
5.3.2. Steroids
5.3.3. Dopamine Antagonists
5.3.4. Neurokinin NK-1 Receptor Antagonists
5.3.5. Non-pharmacological Treatment
5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
6.3.1. Hospital Pharmacies
6.3.2. Online Pharmacies
6.3.3. Retail Pharmacies and Drug Stores
6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. South Asia
7.3.5. East Asia
7.3.6. Oceania
7.3.7. MEA
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Treatment Type
8.2.3. By Distribution Channel
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment Type
8.3.3. By Distribution Channel
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Treatment Type
9.2.3. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment Type
9.3.3. By Distribution Channel
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Treatment Type
10.2.3. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment Type
10.3.3. By Distribution Channel
10.4. Key Takeaways
11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. India
11.2.1.2. Malaysia
11.2.1.3. Singapore
11.2.1.4. Thailand
11.2.1.5. Rest of South Asia
11.2.2. By Treatment Type
11.2.3. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment Type
11.3.3. By Distribution Channel
11.4. Key Takeaways
12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Treatment Type
12.2.3. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment Type
12.3.3. By Distribution Channel
12.4. Key Takeaways
13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. Australia
13.2.1.2. New Zealand
13.2.2. By Treatment Type
13.2.3. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Treatment Type
13.3.3. By Distribution Channel
13.4. Key Takeaways
14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Treatment Type
14.2.3. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Treatment Type
14.3.3. By Distribution Channel
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Treatment Type
15.1.2.2. By Distribution Channel
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Treatment Type
15.2.2.2. By Distribution Channel
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Treatment Type
15.3.2.2. By Distribution Channel
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Treatment Type
15.4.2.2. By Distribution Channel
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Treatment Type
15.5.2.2. By Distribution Channel
15.6. United kingdom
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Treatment Type
15.6.2.2. By Distribution Channel
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Treatment Type
15.7.2.2. By Distribution Channel
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Treatment Type
15.8.2.2. By Distribution Channel
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Treatment Type
15.9.2.2. By Distribution Channel
15.10. India
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Treatment Type
15.10.2.2. By Distribution Channel
15.11. Malaysia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Treatment Type
15.11.2.2. By Distribution Channel
15.12. Singapore
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Treatment Type
15.12.2.2. By Distribution Channel
15.13. Thailand
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Treatment Type
15.13.2.2. By Distribution Channel
15.14. China
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Treatment Type
15.14.2.2. By Distribution Channel
15.15. Japan
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Treatment Type
15.15.2.2. By Distribution Channel
15.16. South Korea
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Treatment Type
15.16.2.2. By Distribution Channel
15.17. Australia
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Treatment Type
15.17.2.2. By Distribution Channel
15.18. New Zealand
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Treatment Type
15.18.2.2. By Distribution Channel
15.19. GCC Countries
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Treatment Type
15.19.2.2. By Distribution Channel
15.20. South Africa
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Treatment Type
15.20.2.2. By Distribution Channel
15.21. Israel
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Treatment Type
15.21.2.2. By Distribution Channel
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Treatment Type
16.3.3. By Distribution Channel
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Acacia Pharma
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. F. Hoffmann-La Roche AG
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Novartis AG
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Ani Pharmaceuticals, Inc.
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Camurus AB
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Sanofi S.A.
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Helsinn Holding S.A.
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Eisai Corporation
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Merck and Co.
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. GlaxoSmithKline Corporation
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Postoperative Nausea and Vomiting (PONV) Management Market
